Derivation Web

source_d049c2806fbc4696

by researka:v2 · 2026-05-28 23:51:00.170150+04:00

{"contradictions": ["What does the current evidence establish about Coenzyme Q10 Ubiquinol and human geroscience? This synthesis tests the thesis that evidence for Coenzyme Q10 ubiquinol is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes coenzyme q10 ubiquinol as an aging-related intervention across 63 included source papers and 3843 high-confidence extracted claims. The evidence profile contains 7 direct clinical sources, 24 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 283 cross-study disagreements across the evidence base. Positive study-level signals concentrate in longevity, contextual adjacent evidence, mortality and survival, null signals in dosing and pharmacokinetics, contextual adjacent evidence, safety and comorbidity, and negative signals in cardiometabolic. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that coenzyme q10 ubiquinol remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not", "A notable tension within the corpus concerns the consistency of oxidative stress outcomes across clinical populations. While Yeung 2015 and Moccia 2019 reported significant reductions in oxidative and inflammatory markers, the clinical RCT in burn patients (Kiani 2024) found no significant effect on its primary malondialdehyde endpoint (P = 0.550). Similarly, Greenlee 2025 observed no clinically concerning pharmacokinetic interference between CoQ10 and doxorubicin, supporting a favorable safety profile in oncology. The disagreement between the clear positive oxidative findings in some cohorts and the null primary result in the burn patient trial may reflect differences in baseline oxidative burden, disease pathology, or the specific biomarker endpoints chosen across studies.", "The evidence base for coenzyme Q10 (CoQ10) supplementation and immune/inflammatory outcomes spans multiple study designs, including clinical RCTs in specific patient populations, observational cohorts, and several systematic reviews and meta-analyses. In a randomized, placebo-controlled trial in hepatocellular carcinoma patients after surgery, Liu 2016 investigated CoQ10 supplementation's effects on oxidative stress and inflammation, with mixed results across multiple measured endpoints. The umbrella meta-analysis by Varnousfaderani 2023 synthesized data across studies to evaluate CoQ10's effects on biomarkers of inflammation and oxidative stress in adults. Additional systematic reviews by Zhai 2017, Jorat 2019, Alimohammadi 2021, and Xu 2022 examined various inflammatory markers in coronary artery disease, breast cancer, and chronic kidney disease populations.", "Within the corpus, notable tensions exist regarding the magnitude and consistency of CoQ10's anti-inflammatory effects across different study contexts. The Zhai 2017 systematic review reported unclear overall direction of effect on inflammatory markers, while Jorat 2019 in coronary artery disease found consistent significant reductions across multiple biomarkers. Furthermore, Alehagen 2022b's analysis of a selenium and CoQ10 intervention trial reported null findings for certain immune-related biomarkers (P < 0.001 for some endpoints but with a reported null overall effect direction), creating tension with the positive signal from Dahri 2019. The retracted PCOS study by Rahmani 2018 reported improvements in gene expression related to inflammation, adding further heterogeneity to the evidence base.", "Tensions within this outcome class reflect heterogeneity in study populations, interventions, and endpoints. Spiegeleer (2025) reports a negative cardiometabolic association in older adults, whereas Zhang (2026) documents positive pooled effects on glycemic and lipid parameters across metabolic disorder populations. Zhang (2018) presents a mixed profile with some significant lipid improvements but an unclear overall effect direction, contrasting with the uniformly positive summary estimates in Zhang (2026). Several sources are systematic reviews and meta-analyses examining outcomes in populations where statin use is a key variable, such as heart failure and aortic aneurysm (Bielecka-Dabrowa 2019, Liao 2019). Other studies directly investigate CoQ10 or ubiquinol in clinical or mechanistic contexts, including a randomized controlled trial on ovarian response in women with decreased ovarian reserve (Xu 2018) and a sub-analysis of a double-blind placebo-controlled trial on selenium and CoQ10 in elderly individuals (Alehagen 2023). The corpus also includes systematic reviews on fertility in ovarian aging (Shang 2024), dietary strategies in heart failure (Yu 2024), and the comparative bioavailability of CoQ10 formulations in healthy elderly individuals (Pravst 2020). These studies collectively provide evidence on diverse endpoints, from mortality and metabolic profiles to reproductive and inflammatory outcomes.", "The corpus presents several within-corpus tensions regarding effect directions and significance. For instance, Bielecka-Dabrowa 2019 reports a strong positive association between statin use and reduced mortality in heart failure, while Symvoulidis 2023 finds a non-significant reduction in bladder cancer risk with statin use. Similarly, Shang 2024 presents unclear or mixed effects of CoQ10 on fertility outcomes, which contrasts with the more definitive changes in aging biomarkers reported in Alehagen 2023. Studies investigating direct CoQ10 supplementation, such as Pravst 2020 on bioavailability and Diaz-Castro 2020 on exercise, report significant effects on pharmacokinetic or physiological markers (P < 0.05), while some broader reviews note null findings for clinical endpoints (Yu 2024). These disagreements highlight the context-dependency of CoQ10's effects and the influence of study design, population, and specific endpoints on observed outcomes."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "b8dee5f7-0023-4af5-bacc-446de915555a", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 63, "included": 63, "included_or_retained": 63, "screened": 63, "wording": "63 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "b8dee5f7-0023-4af5-bacc-446de915555a",
  "researka_submission_id": "d634654e-17d4-4dad-8977-cb586fa6e83d",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/b8dee5f7-0023-4af5-bacc-446de915555a/sidecars/contradiction_map.json"
}